The antibody carries a radioactive payload that destroys the tumor from within
En Málaga, uno de cada ocho hombres recibirá a lo largo de su vida un diagnóstico de cáncer de próstata, una enfermedad que a menudo se anuncia con señales tan cotidianas como levantarse a orinar por la noche. La oncología española ha incorporado recientemente el Lutecio-177-PSMA, un anticuerpo radiactivo que lleva la radiación directamente a las células tumorales y ha demostrado reducir el riesgo de muerte en un 38% en pacientes con enfermedad metastásica. Este avance recuerda que la medicina avanza no solo en grandes saltos, sino en meses ganados —meses que, para quien los vive, lo son todo.
- El cáncer de próstata afecta a uno de cada ocho hombres en Málaga, y sus síntomas más comunes —como la nicturia— son tan fáciles de ignorar que la enfermedad suele detectarse tarde.
- En los casos metastásicos, cuando el tumor se ha extendido más allá de la pelvis, las opciones quirúrgicas desaparecen y el tratamiento se convierte en una carrera contra el tiempo para frenar el avance.
- El Lutecio-177-PSMA, financiado en España desde finales de 2025, representa un cambio de paradigma: un anticuerpo que localiza y destruye las células cancerosas desde dentro con una precisión sin precedentes.
- El ensayo clínico VISION demostró que los pacientes tratados sobrevivieron de media 15,3 meses frente a los 11,3 del tratamiento estándar, una diferencia que en términos humanos significa meses junto a la familia.
- La investigación no se detiene: nuevos radiofármacos y terapias dirigidas al eje androgénico están en ensayo clínico, ampliando el arsenal disponible para una enfermedad que afecta a millones.
Uno de cada ocho hombres en Málaga se enfrentará alguna vez a un diagnóstico de cáncer de próstata. La enfermedad suele anunciarse de forma discreta: más viajes al baño por la noche, sangre en la orina o el semen. Señales fáciles de atribuir a otras causas, como el agrandamiento benigno de próstata, lo que convierte el retraso diagnóstico en uno de sus mayores peligros.
Cuando aparecen estos síntomas, el recorrido comienza en atención primaria con una analítica de PSA, una exploración física y la revisión del historial clínico. Si hay sospecha, el paciente pasa a urología, donde se evalúa el nivel de PSA, el grado de extensión del tumor y el contexto clínico completo. La biopsia y el tratamiento dependen del estadio alcanzado.
Los cánceres localizados se clasifican según la escala de Gleason y se agrupan por riesgo. Los de bajo riesgo pueden seguirse con vigilancia activa; otros requieren cirugía —robótica o abierta— o radioterapia. Los de alto riesgo incorporan bloqueo hormonal para privar al tumor de testosterona. En la enfermedad metastásica, la cirugía pierde su papel y el tratamiento se centra en la hormonoterapia, a la que se pueden sumar seis ciclos de quimioterapia en los casos con mayor carga tumoral.
El avance más destacado de los últimos años es el Lutecio-177-PSMA, un anticuerpo radiactivo financiado en España desde finales de 2025. El fármaco se une a la proteína PSMA, presente casi exclusivamente en las células del cáncer de próstata, y libera radiación directamente en su interior. El ensayo clínico VISION mostró que los pacientes tratados sobrevivieron una media de 15,3 meses frente a los 11,3 del tratamiento convencional, lo que supone una reducción del 38% en el riesgo de muerte durante el periodo estudiado.
Paralelamente, los inhibidores de PARP ofrecen beneficios a los pacientes con mutaciones en genes de reparación del ADN como BRCA. Y la investigación continúa: nuevos radiofármacos y estrategias para bloquear la vía androgénica están siendo evaluados en ensayos clínicos, con la promesa de tratar con mayor precisión y menor daño colateral una enfermedad que, en silencio, despierta a demasiados hombres en la noche.
One in eight men in Málaga will face a prostate cancer diagnosis at some point in their lives. The disease often announces itself quietly—a man finds himself waking at night to urinate more frequently than before, or noticing blood in his semen or urine. These symptoms can feel ordinary, easy to dismiss, which is part of what makes prostate cancer dangerous. Frequent trips to the bathroom happen for other reasons too: benign prostate enlargement, a condition where the gland simply grows with age and obstructs the flow of urine. The body sends the same signal for different problems.
When a man notices these warning signs, his first stop is his primary care doctor. The evaluation follows a careful sequence. A blood test measures PSA, the prostate-specific antigen. A medical history is taken. A digital rectal exam—a physical palpation of the gland to feel for hardened areas—is performed. If suspicion remains, the patient moves to urology, where doctors assess risk using three factors: the PSA level, how far the cancer has advanced (determined through ultrasound or magnetic resonance imaging), and the patient's full clinical picture. A biopsy may follow. The treatment path depends entirely on what stage the disease has reached.
Early-stage cancers, those confined to the prostate without spread, are classified by a Gleason score—a measure of how abnormal the tumor cells appear under a microscope. Doctors then sort patients into risk groups: low, intermediate, or high. Low-risk patients often receive active surveillance, periodic PSA tests and biopsies to watch for change. Others undergo surgery, which can be performed robotically, through small incisions, or through open incision. Some receive radiation therapy. High-risk patients may add hormone-blocking treatment to their regimen, limiting testosterone—the fuel the tumor needs to grow.
Metastatic prostate cancer, disease that has spread beyond the pelvis to distant sites, demands a different strategy. Surgery loses its purpose. Radiation, if used at all, comes in lower doses. The focus shifts entirely to starving the cancer of testosterone through hormone therapy. These treatments can hold the disease in check for years. When a metastatic patient carries a heavy tumor burden, doctors add six cycles of chemotherapy alongside the hormone blockers, extending control even further.
Recent years have brought new weapons. Doctors now deploy treatments once reserved for advanced stages earlier in the disease course, improving both survival and quality of life. For the ten to fifteen percent of patients whose cancers carry mutations in DNA repair genes—BRCA mutations, which can be inherited or acquired—a class of drugs called PARP inhibitors has shown measurable benefit. But the most striking advance is Lutetio-177-PSMA, a radioactive antibody therapy that arrived in Spain with recent funding in late 2025. The drug works with elegant precision: it is an antibody that binds to PSMA, a protein found almost exclusively on prostate cancer cells. Once attached, the antibody carries a radioactive payload—Lutetio-177—that emits radiation directly into the tumor cell, destroying it from within.
The VISION clinical trial demonstrated the drug's impact. Patients treated with Lutetio-177 survived an average of 15.3 months, compared to 11.3 months for those receiving standard treatment alone. That difference represents a 38 percent reduction in the risk of death during the study period. For men with metastatic disease, months matter. They are months with family, months of living.
Yet even as Lutetio-177 enters clinical practice, researchers are pursuing other paths. Multiple trials are testing additional radiopharmaceuticals and new approaches to blocking the androgen pathway that fuels prostate cancer growth. The disease that silently wakes men in the night is being met with an expanding arsenal, each new tool refined to strike with greater precision and less collateral damage.
Notable Quotes
We focus on blocking testosterone, which is ultimately what feeds the tumor, because it needs testosterone to grow— Oncology department head at Regional Hospital
Many times we diagnose a prostate cancer that we would not have diagnosed with earlier tests, and the patient might have died of another cause without the cancer ever causing problems—sometimes we risk overtreating— Medical oncologist
The Hearth Conversation Another angle on the story
Why does prostate cancer so often announce itself through something as mundane as nighttime urination? Why not a more obvious alarm bell?
Because the prostate sits right where it controls the flow of urine. As it grows—whether from age, benign enlargement, or cancer—it naturally obstructs that passage. The body responds the only way it can. The problem is that this symptom is so common, so ordinary in aging men, that it whispers rather than shouts.
So a man could have cancer and never know it, if he simply accepted the nighttime trips as part of getting older?
Exactly. And that's where the tension lives. Better screening catches more cancers earlier, which saves lives. But it also means we sometimes diagnose cancers that would never have harmed the man—he might die of something else entirely, never knowing the cancer was there. It's a genuine dilemma without a clean answer.
This Lutetio-177 drug—it sounds almost too precise. How does an antibody know to find only cancer cells and not healthy ones?
The cancer cells express a protein called PSMA on their surface. Healthy prostate tissue barely expresses it at all. The antibody is engineered to recognize and bind to that protein specifically. Once it attaches, it delivers its radioactive payload directly into the cell. It's like a guided missile that only recognizes one target.
Four months longer survival—is that the kind of difference that changes a life?
For someone with metastatic cancer, four months is substantial. It's time. But the real measure isn't just duration. It's what those months feel like, whether the treatment itself is tolerable, whether the patient gets to be present for the people he loves. The trial measured survival, but it couldn't measure that.
What happens next? Is Lutetio-177 the end of the story?
No. It's one chapter in a much longer one. Researchers are testing other radiopharmaceuticals, other ways to block the hormones that feed the cancer. The disease adapts, and so must we. The goal is to keep pushing that survival line higher, and to do it with treatments that don't devastate the body in the process.